CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 70 enrolled
Drug / intervention
Omecamtiv Mecarbil (OM) +2 moredrug
Likely dose
Moxifloxacin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04175808
NCT04175808Phase 1Completed
CompareCT.gov

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects

Cytokinetics·interventional·Posted Nov 25, 2019·Updated Mar 30, 2025

In Brief

A Phase 1 clinical trial evaluating Omecamtiv Mecarbil (OM), Placebo, and 1 other intervention for QT Intervals Changes and QTc Intervals Changes. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy adults. The QT interval is the section on an electrocardiogram (ECG) that represents the time it takes for the electrical system to fire an impulse through the ventricles and then recharge, or the time it takes for the heart muscle to contract and then recover.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsQT Intervals Changes, QTc Intervals Changes
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 25, 2019
Enrollment StartNov 14, 2019
Primary CompletionMar 4, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.6 years ago

Interventions

Omecamtiv Mecarbil (OM)drug

Oral solution

Placebodrug

Placebo oral solution

Moxifloxacindrug

400 mg moxifloxacin oral tablet